ESC 365 - The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study

ESC Professional Premium Access

The real-world safety profile of SGLT2 inhibitors among adults 75 years or older: a retrospective, pharmacovigilance study

Session: SGLT2 inhibitors: pearls from recent trials and surveys

Topic: Pharmacotherapy

Speaker: Associate Professor E. Maor (Tel Aviv, IL)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Associate Professor Elad Maor

Sheba Medical Center, Tel Aviv (Israel)

0 follower

3 more presentations in this session

Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF

Speaker: Doctor C. Adamson (Glasgow, GB)

Efficacy of ertugliflozin on hospitalisation for heart failure across the distribution of pre-trial ejection fraction: post hoc analyses of the VERTIS CV trial

Speaker: Doctor A. Pandey (Dallas, US)

Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF

Speaker: Doctor K. Docherty (Glasgow, GB)

Access the full session

SGLT2 inhibitors: pearls from recent trials and surveys

Speakers: Associate Professor E. Maor, Doctor C. Adamson, Doctor A. Pandey, Doctor K. Docherty

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources